Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MF59 is a squalene-based oil-in-water emulsion adjuvant used to enhance the immunogenicity and efficacy of vaccines, particularly influenza vaccines. It stimulates both innate and adaptive immune responses through various mechanisms including cytokine/chemokine release, immune cell recruitment, antigen retention, and dendritic cell maturation. It is considered safe and well-tolerated, with extensive use in human vaccines.
MF59 enhances immune responses by inducing chemokine and cytokine release, promoting recruitment of immune cells, facilitating antigen retention and presentation, and stimulating dendritic cell maturation. It also triggers cell death pathways (necroptosis and apoptosis) in lymph nodes, leading to enhanced antigen cross-presentation and CD8 T cell responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Squalene-based Oil-in-Water Emulsion Adjuvant (MF59) (MF59).